This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

This database contains 457 studies, archived under the term: "drug therapy"

Click here to filter this large number of results.

Safety and effectiveness of donepezil on behavioral symptoms in patients with Alzheimer disease
The objective of this study was to evaluate the prevalence and treatment responsiveness of neuropsychiatric symptoms in patients with mild to moderately severe Alzheimer disease recruited in a naturalistic treatment setting in Spain. All the patients, who matched the prescribing recommendations for donepezil and were able to participate in the study, received donepezil (5 to […]

Diagnosis of Alzheimer’s disease patients with rapid cognitive decline in clinical practice: interest of the Deco questionnaire
Background: Patients with Alzheimer’s disease (AD) who deteriorate rapidly are likely to have a poorer prognosis. There is a clear need for a clinical assessment tool to detect such a decline in newly diagnosed patients.; Objective: To identify the predictive factors of rapid cognitive decline (RCD) in a cohort of patients with mild to moderate […]

Effect of TTP488 in patients with mild to moderate Alzheimer’s disease
Background: TTP488, an antagonist at the Receptor for Advanced Glycation End products, was evaluated as a potential treatment for patients with mild-to-moderate Alzheimer’s disease (AD). A previous report describes decreased decline in ADAS-cog (delta = 3.1, p = 0.008 at 18 months, ANCOVA with multiple imputation), relative to placebo, following a 5 mg/day dose of TTP488. Acute, reversible cognitive […]

The effects of counseling spouse caregivers of people with Alzheimer disease taking donepezil and of country of residence on rates of admission to nursing homes and mortality
Objective: Does psychosocial intervention for caregivers whose spouses with Alzheimer disease (AD) are taking donepezil delay nursing home (NH) placement or death of patients?; Design: Randomized controlled trial with 2 years of active treatment and up to 8.5 years of follow-up (mean: 5.4 years, SD: 2.4).; Setting: Outpatients of research clinics in Australia, the United […]

An evaluation of the effectiveness of a case-specific approach to challenging behaviour associated with dementia
Objectives: Treatment of challenging behaviour in dementia using standardized psychopharmacological or psychosocial approaches remains problematical. A case-specific approach was trialled in this study, based on extensive evidence that each case is different in aetiology, the effects of the behaviour on others and what interventions are possible given the available resources.; Method: Forty-four consecutive referrals for […]

Results of the citalopram to enhance cognition in Huntington disease trial
Background: The objective of this study was to evaluate citalopram for executive functioning in Huntington’s disease (HD).; Methods: The study was randomized, double-blind, and placebo-controlled. Thirty-three adults with HD, cognitive complaints, and no depression (Hamilton Depression [HAM-D] rating scale ≤ 12) were administered citalopram 20 mg or placebo (7 visits, 20 weeks), with practice and […]

Gait changes with anti-dementia drugs: a prospective, open-label study combining single and dual task assessments in patients with Alzheimer’s disease
Background: No comparison of anti-dementia drugs-related gait changes has been previously conducted combining single and dual task assessments.; Objectives: (1) To quantify and compare gait changes among patients with possible or probable Alzheimer’s disease before and after the use of acetylcholinesterase inhibitors (i.e., donepezil, galantamine, rivastigmine) or memantine, and among controls with possible or probable […]

Escitalopram versus risperidone for the treatment of behavioral and psychotic symptoms associated with Alzheimer’s disease: a randomized double-blind pilot study
Background: Antipsychotics are frequently used to treat psychosis, aggression and agitation in patients with Alzheimer’s disease (AD), but safety warnings abound. Escitalopram was investigated since citalopram has demonstrated some effectiveness in AD. We compared escitalopram and risperidone for psychotic symptoms and agitation associated with AD.; Methods: Inpatients with AD, who had been hospitalized because of […]

Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial
Background: Depression is common in dementia but the evidence base for appropriate drug treatment is sparse and equivocal. We aimed to assess efficacy and safety of two of the most commonly prescribed drugs, sertraline and mirtazapine, compared with placebo.; Methods: We undertook the parallel-group, double-blind, placebo-controlled, Health Technology Assessment Study of the Use of Antidepressants […]

The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial
Background: Data from 12-week placebo-controlled trials have led to mounting concerns about increased mortality in patients with Alzheimer’s disease (AD) who are prescribed antipsychotics; however, there are no mortality data from long-term placebo-controlled trials. We aimed to assess whether continued treatment with antipsychotics in people with AD is associated with an increased risk of mortality.; […]

Try searching our database by another keyword...

To make a new query of the database, please enter your search terms below:

�

Contact Us